Localized sequence-specific release of a chemopreventive agent and an anticancer drug in a time-controllable manner to enhance therapeutic efficacy

Wen Yu Pan, Kun Ju Lin, Chieh Cheng Huang, Wei Lun Chiang, Yu Jung Lin, Wei Chih Lin, Er-Tuan Chuang, Yen Chang, Hsing Wen Sung

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Combination chemotherapy with multiple drugs commonly requires several injections on various schedules, and the probability that the drug molecules reach the diseased tissues at the proper time and effective therapeutic concentrations is very low. This work elucidates an injectable co-delivery system that is based on cationic liposomes that are adsorbed on anionic hollow microspheres (Lipos-HMs) via electrostatic interaction, from which the localized sequence-specific release of a chemopreventive agent (1,25(OH)2D3) and an anticancer drug (doxorubicin; DOX) can be thermally driven in a time-controllable manner by an externally applied high-frequency magnetic field (HFMF). Lipos-HMs can greatly promote the accumulation of reactive oxygen species (ROS) in tumor cells by reducing their cytoplasmic expression of an antioxidant enzyme (superoxide dismutase) by 1,25(OH)2D3, increasing the susceptibility of cancer cells to the cytotoxic action of DOX. In nude mice that bear xenograft tumors, treatment with Lipos-HMs under exposure to HFMF effectively inhibits tumor growth and is the most effective therapeutic intervention among all the investigated. These empirical results demonstrate that the synergistic anticancer effects of sequential release of 1,25(OH)2D3 and DOX from the Lipos-HMs may have potential for maximizing DOX cytotoxicity, supporting more effective cancer treatment.

Original languageEnglish
Pages (from-to)241-250
Number of pages10
JournalBiomaterials
Volume101
DOIs
Publication statusPublished - 2016
Externally publishedYes

Fingerprint

Antineoplastic Agents
Tumors
Cells
Pharmaceutical Preparations
Magnetic fields
Magnetic Fields
Neoplasms
Oncology
Chemotherapy
Liposomes
Cytotoxicity
Coulomb interactions
Antioxidants
Microspheres
Heterografts
Doxorubicin
Superoxide Dismutase
Reactive Oxygen Species
Therapeutics
Enzymes

Keywords

  • Chemopreventive agent
  • Combination chemotherapy
  • Reactive oxygen species
  • Sequential drug release
  • Synergistic anticancer effect

ASJC Scopus subject areas

  • Bioengineering
  • Ceramics and Composites
  • Biophysics
  • Biomaterials
  • Mechanics of Materials

Cite this

Localized sequence-specific release of a chemopreventive agent and an anticancer drug in a time-controllable manner to enhance therapeutic efficacy. / Pan, Wen Yu; Lin, Kun Ju; Huang, Chieh Cheng; Chiang, Wei Lun; Lin, Yu Jung; Lin, Wei Chih; Chuang, Er-Tuan; Chang, Yen; Sung, Hsing Wen.

In: Biomaterials, Vol. 101, 2016, p. 241-250.

Research output: Contribution to journalArticle

Pan, Wen Yu ; Lin, Kun Ju ; Huang, Chieh Cheng ; Chiang, Wei Lun ; Lin, Yu Jung ; Lin, Wei Chih ; Chuang, Er-Tuan ; Chang, Yen ; Sung, Hsing Wen. / Localized sequence-specific release of a chemopreventive agent and an anticancer drug in a time-controllable manner to enhance therapeutic efficacy. In: Biomaterials. 2016 ; Vol. 101. pp. 241-250.
@article{c3b28f6153034755bc36609d2c22a527,
title = "Localized sequence-specific release of a chemopreventive agent and an anticancer drug in a time-controllable manner to enhance therapeutic efficacy",
abstract = "Combination chemotherapy with multiple drugs commonly requires several injections on various schedules, and the probability that the drug molecules reach the diseased tissues at the proper time and effective therapeutic concentrations is very low. This work elucidates an injectable co-delivery system that is based on cationic liposomes that are adsorbed on anionic hollow microspheres (Lipos-HMs) via electrostatic interaction, from which the localized sequence-specific release of a chemopreventive agent (1,25(OH)2D3) and an anticancer drug (doxorubicin; DOX) can be thermally driven in a time-controllable manner by an externally applied high-frequency magnetic field (HFMF). Lipos-HMs can greatly promote the accumulation of reactive oxygen species (ROS) in tumor cells by reducing their cytoplasmic expression of an antioxidant enzyme (superoxide dismutase) by 1,25(OH)2D3, increasing the susceptibility of cancer cells to the cytotoxic action of DOX. In nude mice that bear xenograft tumors, treatment with Lipos-HMs under exposure to HFMF effectively inhibits tumor growth and is the most effective therapeutic intervention among all the investigated. These empirical results demonstrate that the synergistic anticancer effects of sequential release of 1,25(OH)2D3 and DOX from the Lipos-HMs may have potential for maximizing DOX cytotoxicity, supporting more effective cancer treatment.",
keywords = "Chemopreventive agent, Combination chemotherapy, Reactive oxygen species, Sequential drug release, Synergistic anticancer effect",
author = "Pan, {Wen Yu} and Lin, {Kun Ju} and Huang, {Chieh Cheng} and Chiang, {Wei Lun} and Lin, {Yu Jung} and Lin, {Wei Chih} and Er-Tuan Chuang and Yen Chang and Sung, {Hsing Wen}",
year = "2016",
doi = "10.1016/j.biomaterials.2016.06.008",
language = "English",
volume = "101",
pages = "241--250",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier Science Ltd",

}

TY - JOUR

T1 - Localized sequence-specific release of a chemopreventive agent and an anticancer drug in a time-controllable manner to enhance therapeutic efficacy

AU - Pan, Wen Yu

AU - Lin, Kun Ju

AU - Huang, Chieh Cheng

AU - Chiang, Wei Lun

AU - Lin, Yu Jung

AU - Lin, Wei Chih

AU - Chuang, Er-Tuan

AU - Chang, Yen

AU - Sung, Hsing Wen

PY - 2016

Y1 - 2016

N2 - Combination chemotherapy with multiple drugs commonly requires several injections on various schedules, and the probability that the drug molecules reach the diseased tissues at the proper time and effective therapeutic concentrations is very low. This work elucidates an injectable co-delivery system that is based on cationic liposomes that are adsorbed on anionic hollow microspheres (Lipos-HMs) via electrostatic interaction, from which the localized sequence-specific release of a chemopreventive agent (1,25(OH)2D3) and an anticancer drug (doxorubicin; DOX) can be thermally driven in a time-controllable manner by an externally applied high-frequency magnetic field (HFMF). Lipos-HMs can greatly promote the accumulation of reactive oxygen species (ROS) in tumor cells by reducing their cytoplasmic expression of an antioxidant enzyme (superoxide dismutase) by 1,25(OH)2D3, increasing the susceptibility of cancer cells to the cytotoxic action of DOX. In nude mice that bear xenograft tumors, treatment with Lipos-HMs under exposure to HFMF effectively inhibits tumor growth and is the most effective therapeutic intervention among all the investigated. These empirical results demonstrate that the synergistic anticancer effects of sequential release of 1,25(OH)2D3 and DOX from the Lipos-HMs may have potential for maximizing DOX cytotoxicity, supporting more effective cancer treatment.

AB - Combination chemotherapy with multiple drugs commonly requires several injections on various schedules, and the probability that the drug molecules reach the diseased tissues at the proper time and effective therapeutic concentrations is very low. This work elucidates an injectable co-delivery system that is based on cationic liposomes that are adsorbed on anionic hollow microspheres (Lipos-HMs) via electrostatic interaction, from which the localized sequence-specific release of a chemopreventive agent (1,25(OH)2D3) and an anticancer drug (doxorubicin; DOX) can be thermally driven in a time-controllable manner by an externally applied high-frequency magnetic field (HFMF). Lipos-HMs can greatly promote the accumulation of reactive oxygen species (ROS) in tumor cells by reducing their cytoplasmic expression of an antioxidant enzyme (superoxide dismutase) by 1,25(OH)2D3, increasing the susceptibility of cancer cells to the cytotoxic action of DOX. In nude mice that bear xenograft tumors, treatment with Lipos-HMs under exposure to HFMF effectively inhibits tumor growth and is the most effective therapeutic intervention among all the investigated. These empirical results demonstrate that the synergistic anticancer effects of sequential release of 1,25(OH)2D3 and DOX from the Lipos-HMs may have potential for maximizing DOX cytotoxicity, supporting more effective cancer treatment.

KW - Chemopreventive agent

KW - Combination chemotherapy

KW - Reactive oxygen species

KW - Sequential drug release

KW - Synergistic anticancer effect

UR - http://www.scopus.com/inward/record.url?scp=84979276861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979276861&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2016.06.008

DO - 10.1016/j.biomaterials.2016.06.008

M3 - Article

VL - 101

SP - 241

EP - 250

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

ER -